172 related articles for article (PubMed ID: 36503448)
1. Immunotherapy-Associated Hypophysitis under Anti-PD1: Two Case Reports.
Shen X; Yang M; Xu H; Zhou H; Wang L; Ma J
Endocr Metab Immune Disord Drug Targets; 2023; 23(7):996-1004. PubMed ID: 36503448
[TBL] [Abstract][Full Text] [Related]
2. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
3. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
4. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Fernandes S; Varlamov EV; McCartney S; Fleseriu M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy-associated hypophysitis.
Solinas C; Porcu M; De Silva P; Musi M; Aspeslagh S; Scartozzi M; Willard-Gallo K; Mariotti S; Saba L
Semin Oncol; 2018 Jun; 45(3):181-186. PubMed ID: 30352754
[TBL] [Abstract][Full Text] [Related]
6. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
Han X; Meng M; Zhang T; Wang J; Huang G; Ni Y; Li W; Dai J; Yang X; Ye X
J Cancer Res Ther; 2022 Sep; 18(5):1440-1443. PubMed ID: 36204895
[TBL] [Abstract][Full Text] [Related]
7. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
8. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
12. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
13. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
Deligiorgi MV; Liapi C; Trafalis DT
Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
[TBL] [Abstract][Full Text] [Related]
14. Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report.
Li R; Jiang B; Zhu Y; Gao L; Zhou Y; Yang S
Endocr Metab Immune Disord Drug Targets; 2023 Oct; 24(5):606-10. PubMed ID: 37818555
[TBL] [Abstract][Full Text] [Related]
15. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
16. Two Cases of Atezolizumab-Induced Hypophysitis.
Kanie K; Iguchi G; Bando H; Fujita Y; Odake Y; Yoshida K; Matsumoto R; Fukuoka H; Ogawa W; Takahashi Y
J Endocr Soc; 2018 Jan; 2(1):91-95. PubMed ID: 29362727
[TBL] [Abstract][Full Text] [Related]
17. Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology.
Ducloux R; Tavernier JY; Wojewoda P; Toullet F; Romanet S; Averous V
Ann Endocrinol (Paris); 2021 Feb; 82(1):8-14. PubMed ID: 33290748
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
[No Abstract] [Full Text] [Related]
19. [Checkpoint inhibitors-induced hypophysitis].
du Payrat JA; Cugnet-Anceau C; Maillet D; Levy M; Raverot G; Disse E; Borson-Chazot F
Bull Cancer; 2020 Apr; 107(4):490-498. PubMed ID: 32200950
[TBL] [Abstract][Full Text] [Related]
20. MECHANISMS IN ENDOCRINOLOGY: Hypophysitis: diagnosis and treatment.
Joshi MN; Whitelaw BC; Carroll PV
Eur J Endocrinol; 2018 Sep; 179(3):R151-R163. PubMed ID: 29880706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
